pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·2h ago·1 min read
save

Staggering health insurance premiums force employers to rethink coverage options

Oct 5, 2026·read at STAT ↗Negative

Employers are confronting staggeringly high health insurance premiums, according to a STAT+ newsletter by reporter Bob Herman. The piece highlights how rising costs are forcing some businesses to reconsider whether to offer coverage at all.

The article attributes the premium surge to the industry's high and opaque pricing, including Medicare Advantage plans and prescription drug benefits. These factors are driving the expense to levels that some companies find unsustainable.

The story appears in the subscription-only Health Care Inc. newsletter and invites readers to share their thoughts via email.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Prices, prices, prices”

read at STAT ↗
497 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LILLY2RISING
drugs
pirtobrutinib
topics
CLLRare Disease

related stories

  • 5h agoOptogenetics researchers win a Nobel Prize; Roche bets on Alector brain drugBioPharma Dive
  • Jun 26On second try, Acadia drug gets nod from European regulatorsBioPharma Dive
  • 3h agoSTAT+: Utah plows ahead with more health AI pilots for prescriptions, women’s healthSTAT
  • 5h agoSTAT+: Lilly’s Jaypirca approved as first-line CLL therapySTAT
  • 10h agoSTAT+: Hospital and pharmaceutical prices are smothering America’s businessesSTAT